The objective of drug discovery phase is to synthesize lead compounds, new analogs with improved potency, reduced off target activities, and physiochemical/metabolic properties suggestive of reasonable in vivo pharmacokinetics. This optimization is accomplished through empirical modification of the hit structure and/or by employing structure-based design if structural information about the target is available. The goal of present work is to design drug with minimum side effect and maximum potency. 2D QSAR is planned using Multiple Linear Regression Analysis, for achieving the goal, which can help in recognizing the important descriptor that can help in increasing the potency of anticancer drugs.

The resistance of malaria parasites to widely used drugs prompted an upsurge in the development of new drugs with novel mechanism of action, and re- evaluation of the existing drugs to overcome the resistance problem. A number of new potential target pathways have already been identified and efforts to develop lead compounds for these putative targets hopefully will allow treatment of malaria infections in a uniform sustained way. Considerable research efforts were directed in the areas of chloroquine drug resistance reversal agents. Careful development of some bisquinolines, which are free of toxic side effect, 4-anilinoquinolines and modified chloroquine analogs may be helpful to obtain drug candidates that inhibit the growth of chloroquine sensitive and resistant parasites. In the past several years, new structural classes of antimalarial agents, target based antimalarial agents, iron chelators have made some interesting and promising lead molecules available for further optimization to provide compounds for clinical development.